Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

FDA approves Moderna's mFLUVISA, first mRNA-based flu vaccine, for seasonal influenza prevention in adults 50 and older
Vaccine, infectious disease, mRNA vaccine, influenza, older adults - Read more

FDA approves Takeda's Orzeyful (oveporexton), first orexin receptor 2 agonist, for narcolepsy type 1
Small molecule, neurological, orexin receptor agonist, narcolepsy - Read more

Schrödinger expands Bristol Myers Squibb partnership with large-scale Bunsen AI co-scientist deployment
Research collaboration, AI/ML, drug discovery, small molecule, oncology - Read more

CellFiber, Tidewave Bio collaborate to evaluate scalable 3D manufacturing for solid tumor immunotherapy
Research collaboration, oncology, cell therapy, manufacturing, 3D cell culture - Read more

Adneuris Therapeutics, Maruishi Pharmaceutical strike exclusive license for cebranopadol in Japan and South Korea, $35M upfront
Licensing deal, small molecule, pain, milestone payments, royalties - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Hengrui Pharmaceuticals' (ributatide) GLP-1/GIP dual agonist hits 2.78% HbA1c reduction in Ph3 type 2 diabetes trial
Small molecule, metabolic, GLP-1/GIP dual agonist, type 2 diabetes, semaglutide, HbA1c reduction - Read more

Eli Lilly confident in Foundayo obesity pill growth despite slow U.S. start, strong UAE sales
Small molecule, obesity, competitive, revenue impact - Read more

LifeMine Therapeutics raises $263M in venture financings, advancing novel organ transplant treatment
Transplant medicine, small molecule, fungal genomics, platform technology, calcineurin inhibitor, clinical-stage - Read more

Braveheart Bio raises $382.5M IPO, developing cardiac drug for hypertrophic cardiomyopathy
Cardiovascular, small molecule, hypertrophic cardiomyopathy, clinical-stage - Read more

CDC confirms Erica Schwartz as permanent director, ending year-long leadership vacuum amid political controversy
Public health, infectious disease, operational, regulatory - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Actimed Therapeutics reacquires full rights to wasting disease drug, ending $126M deal with Faraday Pharmaceuticals
Rights reversion, rare disease, small molecule, ALS, muscle wasting - Read more

Emergent BioSolutions eliminates chief medical officer role, cuts 93 jobs, saving $40M annually
Small molecule, infectious disease, cost reduction, operational - Read more

Aurora Therapeutics drops PKU gene-editing program, cuts staff amid growing competition
Gene editing, rare disease, competitive, operational - Read more

AstraZeneca-Bristol Myers Squibb merger rumors denied, source confirms "no deal, no discussions" between companies
Merger denial, oncology, strategic, major transaction - Read more

Sanofi halts Ph2 trial of (SAR445399), anti-interleukin-1 receptor 3 antibody, in non-cystic fibrosis bronchiectasis for strategic reasons
Antibody, respiratory disease, monoclonal antibody, non-cystic fibrosis bronchiectasis, interleukin-1 receptor 3, IL-33 pathway - Read more

Context Therapeutics discontinues (CT-95) mesothelin-CD3 bispecific T-cell engager Ph1 trial to extend cash runway
Antibody, cancer, bispecific T-cell engager, mesothelin, solid tumors - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here